Mode
Text Size
Log in / Sign up
N/A N=10 Treatment

Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-I

Pulmonary Embolism

Enrolled (actual)
10
Serious AEs
10.0%
Results posted
May 2026
Primary outcome: Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Vertex Pulmonary Embolectomy System (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Neptune Medical
Primary completion
Apr 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Right Ventricle/Left Ventricle (RV/LV) Ratio
-0.4
PRIMARY
Major Adverse Events (MAEs)
0; 10

Summary

This study study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of pulmonary embolism.

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years 0.9 on CTA as assessed by investigator (site determined).
  • Systolic blood pressure ≥ 90 mmHg (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with fluids)
  • Subject is willing and able to provide written informed consent prior to receiving any non-standard of care clinical investigation plan specific procedures
  • Subject is willing and able to comply with all clinical investigation plan required follow-up visits

Exclusion Criteria

  • Thrombolytic use within 30 days of baseline CTA
  • Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization (site determined)
  • Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg
  • Unstable heart rate > 130 beats per minute prior to procedure
  • FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%
  • Hematocrit 1.8 mg/dL
  • International normalized ratio (INR) > 3
  • Major trauma injury severity score (ISS) > 15 within the past 14 days
  • Presence of intracardiac lead in the right ventricle or right atrium placed <180 days prior to the index procedure
  • Cardiovascular or pulmonary surgery within last 30 days
  • Actively progressing cancer requiring chemotherapy
  • Known bleeding diathesis or coagulation disorder
  • Left bundle branch block
  • History of severe or chronic pulmonary arterial hypertension
  • History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
  • History of decompensated heart failure
  • Patients on extracorporeal membrane oxygenation (ECMO)
  • History of underlying lung disease that is oxygen dependent
  • History of chest irradiation
  • History of heparin-induced thrombocytopenia (HIT)
  • Contraindication to systemic or therapeutic doses of heparin or anticoagulants
  • Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
  • Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention
  • Life expectancy of < 365 days, as determined by Investigator
  • Female who is pregnant or nursing
  • Current participation in another investigational drug or device treatment study
  • Inability to lay flat for procedure
  • Known presence of right-to-left cardiac shunt
  • History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
  • Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06571760). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search